Use of tranexamic acid in melasma
Journal Title: Український журнал дерматології, венерології, косметології - Year 2019, Vol 0, Issue 3
Abstract
Tranexamic acid (TA) is an old drug used for a long time to treat or prevent excessive blood loss. In the beginning of the 1950s it was discovered that the amino acid lysine was able to inhibit activation of plasminogen, but the effect was too weak to be a candidate for the treatment of fibrinolytic haemorrhagic conditions. The first mention of TA in dermatology was in 1979 in actinic prurigo, with good results. Later it was demonstrated in vitro that TA was able to block melanogenesis. During the 2010’s more and more trials were published, assessing its efficacy in melasma, but also in erythrotelangiectasic rosacea. First, systemic TA was prescribed, but soon, because of the rare but severe complications susceptible of occurring, topical way was tested, giving similar results without risk of side effects. The particular interest of TA in the management of melasma is due to that it displays an activity at various levels. First, TA was shown to downregulate the activity of mast cells and consequently the release of histamine. Following the review of the currently available literature concerning the use of TA in melasma, it appears that this active ingredient permits achieving a good efficacy in this indication where there is no satisfactory therapy, with minor side effects. There are mainly three modalities of treatment of melasma with TA: oral administration and intradermal and topical applications. From the literature reviewed, it appears that the best results can be achieved by intradermal administration of TA (4 mg/l monthly) or topical 3 % TA (2/day). At this stage, the limitations of the currently available data are double: first, most of studies are concerning Asian skin, and secondly there is a lack of a large scale comparative study encompassing these three different ways of administration, which could confirm (or not) our analysis of currently published data.
Authors and Affiliations
C. Diehl
Keywords
Related Articles
- EP ID EP672779
- DOI 10.30978/UJDVK2019-3-104
- Views 100
- Downloads 0
Investigation of the impact of Prostrolane Natural-B on the main pathogenetic links of inflammatory skin aging
Objective — to investigate the effectiveness of Prostrolane Natural-B (injectable biorevitalizant with filling effect) in patients with age-related skin changes based on the dynamics of immunohistochemical markers of inf...
Soap Perolite in treatment of acne
The data are presented of the clinical study of the effectiveness of soap with the brand name Perolite, which includes benzoyl peroxide, and Perolite plus containing benzoyl peroxide and clindamycin for the local treatme...
Comparative analysis of dermoscopy and telerdermoscopy in cases of melanocytic nevi and skin melanoma
Objective — Compare the effectiveness of dermoscopy and teledermoscopy of skin neoplasms through melanocytic nevi and skin melanoma. Materials and methods. For this study 50 skin neoplasms with a previous diagnosis of m...
Chronic urticaria: modern approaches to classification, diagnostics and patients’ management in terms of evidence-based medicine
The article deals with pathogenesis, modern classification and diagnostics for chronic urticaria. The disease is a multidisciplinary and the most spread skin disorder. About 1.8 % among adults and 0.1—0.3 % children expe...
Modern complex treatment of microsporia
Objective — to increase the effectiveness of the treatment of children with microsporia by using Breveluck probiotic-vitamin complex in the complex therapy. Materials and methods. 55 sick children aged from 1 to 13 year...